ARA-290 16MG

ARA-290 is a research peptide that has garnered attention for its potential therapeutic effects, particularly in the context of diabetic neuropathy and other conditions involving nerve damage. It is derived from the erythropoietin (EPO) peptide sequence but is designed to have neuroprotective properties without the erythropoietic effects (increased red blood cell production) associated with EPO.

Research suggests that ARA-290 may help to reduce inflammation and promote nerve repair, making it a candidate for treating various neurological conditions. 

ARA-290 is being studied for several potential benefits, particularly in relation to nerve health and conditions like diabetic neuropathy. Some of the proposed benefits include:

1. **Neuroprotection**: ARA-290 may help protect nerve cells from damage, potentially slowing the progression of neurodegenerative conditions.

2. **Anti-inflammatory Effects**: The peptide may reduce inflammation in nerve tissues, which is often a contributing factor to nerve damage.

3. **Promotion of Nerve Repair**: Research suggests that ARA-290 could aid in the regeneration of peripheral nerves, improving recovery from injuries.

4. **Improvement in Symptoms of Neuropathy**: In studies, ARA-290 has shown promise in alleviating symptoms associated with diabetic neuropathy, such as pain and discomfort.

5. **Non-Erythropoietic Action**: Unlike erythropoietin, ARA-290 does not stimulate red blood cell production, making it a safer option for patients who may be at risk for conditions related to increased blood viscosity.

THIS INFORMATION AND PRODUCT IS INTENDED FOR YOUR LABORATORY RESEARCH AND IS NOT INTENDED TO BE CONSUMED BY HUMANS OR ANIMALS.